Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today reported financial results for the fourth quarter and full-year ended December 31, 2015 and provided an update on the Company's clinical programs.